ArticleMicrobiologyOpen2017
The Rhodococcus equi virulence protein VapA disrupts endolysosome function and stimulates lysosome biogenesis.
Article in MicrobiologyOpen, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Genomic diversity of multidrug-resistantApplied and environmental microbiology · 2026Article
- Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- Protective immune response against Rhodococcus equi: An innate immunity-focused review.Equine veterinary journal · 2025Review
- Article
- Antimicrobial Resistance in Equines: A Growing Threat to Horse Health and Beyond-A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2024Review
- Impact of surface receptors TLR2, CR3, and FcγRIII onInfection and immunity · 2024Article
- The opportunistic intracellular bacterial pathogen Rhodococcus equi elicits type I interferon by engaging cytosolic DNA sensing in macrophages.PLoS pathogens · 2021Article
- Current Trends in Understanding and Managing Equine Rhodococcosis.Animals : an open access journal from MDPI · 2020Review
- The pathogenic actinobacterium Rhodococcus equi: what's in a name?Molecular microbiology · 2019Review
- Chronic cavitary pneumonia by Rhodococcus equi in a highly prevalent tuberculosis country: a diagnosis challenge.Revista do Instituto de Medicina Tropical de Sao Paulo · 2018Article
- VapA of Rhodococcus equi binds phosphatidic acid.Molecular microbiology · 2018Article
- Molecular analysis of the chromosomal 16S rRNA gene and vapA plasmid gene of Polish field strains of R. equi.PloS one · 2018Article
- Rescue of an intracellular avirulent Rhodococcus equi replication defect by the extracellular addition of virulence-associated protein A.The Journal of veterinary medical science · 2017Article
- The Rhodococcus equi virulence protein VapA disrupts endolysosome function and stimulates lysosome biogenesis.MicrobiologyOpen · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Rhodococcus equi (R. equi) is an important pulmonary pathogen in foals that often leads to the death of the horse. The bacterium harbors a virulence plasmid that encodes numerous virulence-associated proteins (Vaps) including VapA that is essential for intracellular survival inside macrophages. However, little is known about the precise function of VapA. Here, we demonstrate that VapA causes perturbation to late endocytic organelles with swollen endolysosome organelles having reduced Cathepsin B activity and an accumulation of LBPA, LC3 and Rab7. The data are indicative of a loss of endolysosomal function, which leads cells to upregulate lysosome biogenesis to compensate for the loss of functional endolysosomes. Although there is a high degree of homology of the core region of VapA to other Vap proteins, only the highly conserved core region of VapA, and not VapD of VapG, gives the observed effects on endolysosomes. This is the first demonstration of how VapA works and implies that VapA aids R. equi survival by reducing the impact of lysosomes on phagocytosed bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.